Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo  >  Tosoh Corporation    4042   JP3595200001

TOSOH CORPORATION

(4042)
  Report  
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Tosoh : Launches Sales of World's First Antibody Drug Activity Analysis Column

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/11/2019 | 08:15pm EDT

Tokyo, Japan- As of February 2019, Tosoh Corporation has launched sales worldwide of its TSKgel® FcR-IIIA-NPR. This is the world's first FcR affinity chromatography analysis column for antibody drugs. It is designed to analyze the structure and activity of antibody drugs and was developed independently by Tosoh.

TSKgel FcR-IIIA-NPR uses the human Fcg receptor IIIa as a ligand. Filled with an Fc receptor immobilized packing material, the column enables antibody separation based on the differences in the carbohydrate structure of an antibody that is affecting antibody-dependent cellular cytotoxicity (ADCC).

The biopharmaceutical industry is expanding not only in Japan, the United States, and in other advanced countries in Europe, but also in emerging nations, such as China and India. And demand for antibody drugs is robust. In the research and development of, and manufacturing of antibody drugs, analyzing the activity of antibodies that serve as active pharmaceutical ingredients is essential.

Tosoh offers an assortment of high-performance liquid chromatography (HPLC) and ultrahigh-performance liquid chromatography (UHPLC) columns ideally suited for antibody analysis in antibody drug R&D and manufacturing. Tosoh will continue to bring new products to market to further the profitability of its bioscience business.

  1. Characteristics of TSKgel FcR-IIIA-NPR

Unique separation: TSKgel FcR-IIIA-NPR's unique separation characteristics enable the recognition of amino acid structural changes in the Fc region caused by the differences of antibody N-linked glycoforms, and the separation of antibodies of differing ADCC activity. The column tends to retain antibodies displaying high ADCC activity.

Excellent stability: Fc receptor stability is improved significantly by molecular modification using protein engineering technology. The stable Fc receptor allows accurate and reproducible analysis.

Short-time analysis:

Direct analysis of the antibody molecules can be achieved in as short a time as 30 minutes.

  1. Characteristics of antibody drugs

Characterized by high therapeutic effect and minimal side effects, antibody drugs are increasingly used worldwide to treat cancer and autoimmune diseases, such as rheumatoid arthritis. They are expected to have the highest rate of growth among biopharmaceuticals.

The difference in the carbohydrate structure of antibody drugs affects their binding affinity with Fcg receptor IIIa expressed on the surface of immune cells and their antibody activities such as ADCC activity that destroys cancer and other cells.

* A portion of this research was partially supported by the development key technologies for discovering and manufacturing pharmaceuticals used for next generation treatments and diagnoses both from the Ministry of Economy, Trade and Industry, Japan (METI) and from Japan Agency for Medical Research and Development (AMED).

(Issue No. JP17ae0101003)

Who We Are

Tosoh is the parent of the Tosoh Group, which comprises over 100 companies worldwide and a multiethnic workforce of over 12,000 people and generated net sales of ¥822.9 billion (US$7.4 billion at the average rate of ¥110.85 to the US dollar) in fiscal 2018, ended March 31, 2018.

What We Do

Tosoh is one of the largest chlor-alkali manufacturers in Asia. The company supplies the plastic resins and an array of the basic chemicals that support modern life. Tosoh's petrochemical operations supply ethylene, polyethylene, and functional polymers, while its advanced materials business serves the global semiconductor, display, and solar industries. Tosoh has also pioneered sophisticated bioscience systems that are used for the monitoring of life-threatening diseases. In addition, Tosoh demonstrates its commitment to a sustainable future in part by manufacturing a variety of eco-products.

Stock Exchange Ticker Symbol: 4042

Disclaimer

This document may contain forward-looking statements, including, without limitation, statements concerning product development, objectives, goals, and commercial introductions, which involve certain risks and uncertainties. Forward-looking statements are identified through the use of the word anticipates and other words of similar meaning. Actual results may differ significantly from the results expressed in forward-looking statements.

Disclaimer

Tosoh Corporation published this content on 12 February 2019 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 12 February 2019 01:14:06 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on TOSOH CORPORATION
03/27TOSOH CORPORATION : Ex-dividend day for final dividend
FA
03/23TOSOH : Bioscience Introduces LenS3 Multi-Angle Light Scattering Detector at Pit..
AQ
03/12TOSOH : Receives Technology Prize at 65th Okochi Memorial Foundation Awards
PU
02/12TOSOH : Launches Sales of World's First Antibody Drug Activity Analysis Column
AQ
02/11TOSOH : Launches Sales of World's First Antibody Drug Activity Analysis Column
PU
02/04TOSOH : Reports Its Consolidated Results for the First Nine Months of Fiscal 201..
AQ
01/30TOSOH CORPORATION : quaterly earnings release
01/10TOSOH CORPORATION : Invests in Semba Biosciences, Inc
AQ
2018TOSOH : Bioscience LLC invests in Semba Biosciences
AQ
2018TOSOH : Issues Corrections to its Consolidated Results for the First Half of Fis..
PU
More news
Financials (JPY)
Sales 2019 866 B
EBIT 2019 -
Net income 2019 72 020 M
Finance 2019 15 511 M
Yield 2019 3,17%
P/E ratio 2019 7,98
P/E ratio 2020 8,86
EV / Sales 2019 0,65x
EV / Sales 2020 0,64x
Capitalization 579 B
Chart TOSOH CORPORATION
Duration : Period :
Tosoh Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TOSOH CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 1 716  JPY
Spread / Average Target -3,6%
EPS Revisions
Managers
NameTitle
Toshinori Yamamoto President & Representative Director
Satoru Yonezawa Executive Officer & Manager-Finance
Keiichiro Nishizawa Director & Manager-Engineering Sector
Katsushi Tashiro Representative Director
Koji Kawamoto Director, Manager-Administration & Head-Secretary
Sector and Competitors
1st jan.Capitalization (M$)
TOSOH CORPORATION29.74%5 175
SAUDI BASIC INDUSTRIES CORPORATION SJSC--.--%98 733
AIR LIQUIDE9.73%56 916
SHIN-ETSU CHEMICAL CO LTD27.19%40 062
LYONDELLBASELL INDUSTRIES6.61%32 833
WANHUA CHEMICAL GROUP62.67%21 234